Tag: stage

Achieves Positive Net Income in the Second Quarter and Positive Adjusted EBITDA¹ for the Second Quarter and Six Months Ended June 30, 2025 

Langenfeld, Germany, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Booking Health, a global leader in medical treatment coordination, today unveiled a new study titled Role of Immunotherapy in Extending Life Expectancy for Stage 4 Cervical Cancer Patients. The report outlines how cutting-edge immunotherapy is reshaping care for women with advanced cervical cancer, offering new pathways to longer survival and improved quality of life, particularly in cases resistant to standard treatments.

WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced its top-line revenue forecast for its specialty care pipeline, projecting nearly $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $18 billion and $22 billion. This forecast reflects the company’s unique, faster, and cost-efficient drug development model which has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come.

SYDNEY, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Vast Renewables (“Vast” or the “Company”), a leading Australian clean energy technology company, today announced that it has secured new funding from existing shareholders and launched a capital raise to support the delivery of its flagship Port Augusta Green Energy Hub and growing international project pipeline. Vast also shared several major milestones for its flagship project, Vast Solar 1 (“VS1”), including environmental approvals and grid connection progress.